

INOVIQ APPOINTS BIOTECH LEADER DR EMMA BALL AS CHIEF COMMERCIAL OFFICER

-
- Dr Emma Ball appointed Chief Commercial Officer (CCO), effective 22 April 2025
 - Extensive business development/licensing expertise, commercial experience and networks in therapeutics, vaccines and diagnostics from CSL Ltd and Illumina Inc
-

INOVIQ Limited (ASX: IIQ) is pleased to announce the appointment of Dr Emma Ball BSc PhD MBA GAICD as Chief Commercial Officer (CCO), effective 22 April 2025. Emma will provide commercial leadership across business development, licensing, marketing and sales to advance the commercialisation of INOVIQ technologies and products.

Dr Ball is a biotechnology commercialisation expert with 25 years of experience in strategic and operational roles spanning therapeutics, vaccines and diagnostics. Emma joins INOVIQ from US-headquartered genomics and precision health leader, Illumina Inc (NASDAQ: ILMN), where she was Global Head of Ecosystem Development and responsible for strategic partnerships. Previously, Emma spent 15 years at CSL Limited (ASX: CSL) in various leadership roles in business development and licensing, corporate strategy, commercial development and R&D program management. She led search and evaluation, due diligence and negotiations for multiple transactions including research collaborations, co-development, in- and out-licensing deals, and mergers, acquisitions and divestments.

Emma is based in Melbourne and is currently Non-Executive Chair of BioMelbourne Network, the peak industry body for the Victorian health technologies sector. She trained originally as a molecular biologist and has a PhD from the University of Melbourne and an MBA from RMIT University.

Dr Emma Ball commented: *“I am thrilled to be joining INOVIQ at such a pivotal time in the company’s growth. I was drawn to INOVIQ’s diverse portfolio of diagnostics, therapeutics and research tools, underpinned by its novel exosome technology platform. I will leverage my commercialisation and partnering expertise to accelerate development and accessibility of innovative diagnostics and therapeutics for cancer and other critical diseases.”*

CEO Dr Learne Hinch said: *“We are delighted to welcome Emma to the team during this pivotal period as we advance our ovarian cancer screening test towards clinical trials and CAR-exosome therapy into in vivo efficacy studies for breast cancer. Her expertise in business development, commercial strategy and building strong pharma partnerships will be instrumental in driving the strategic partnering of our SubB2M and EXO-NET technologies, expanding our exosome business, and delivering next-gen diagnostics and therapeutics to patients, clinicians and the healthcare system.”*

Authorised by the Company Secretary, Mark Edwards.

FURTHER INFORMATION

Dr Learne Hinch
Chief Executive Officer
E lhinch@inoviq.com
M +61 400 414 416

ABOUT INOVIQ LTD

INOVIQ Ltd (ASX:IIQ) is a biotechnology company pioneering next-generation diagnostics and therapeutics for cancer. INOVIQ has commercialised its fast, efficient and scalable EXO-NET exosome isolation technology for biomarker discovery and diagnostics development, and the hTERT test as an adjunct test for bladder cancer. The company is advancing clinical-stage diagnostics for detection and monitoring of ovarian and breast cancers, and early-stage exosome therapeutics for solid tumours. For more information on INOVIQ, visit www.inoviq.com.